Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s Osivelotor?

Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease.

Jul 2, 2024 - 04:00
Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of PMV Pharmaceut...

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Idreb...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Commercial drug manufacturing companies for the pharmaceutical industry

Commercial drug manufacturing companies for the pharmac...

Sep 22, 2024

STAT+: UnitedHealth Group now employs or is affiliated with 10% of all physicians in the U.S.

STAT+: UnitedHealth Group now employs or is affiliated ...

Nov 29, 2023

FDA greenlights Regeneron’s Dupixent for the treatment of COPD

FDA greenlights Regeneron’s Dupixent for the treatment ...

Sep 28, 2024